Clinical trials have evaluated the overall efficacy of surfactant therapy, as well as the relative efficacy of different surfactant preparations, the optimal timing of administration and the optimal dosage. Surfactant therapy leads to significant clinical improvement in infants at risk for, or having, respiratory distress syndrome (RDS). Clinical trials that compared the effects of synthetic or animal-derived surfactant preparations to placebo or no therapy demonstrate that surfactant therapy lead to rapid improvement in oxygenation, decreased ventilator support, decreased risk of pneumothorax, and mortality. Earlier treatment, prophylactic treatment of infants at high risk of developing RDS, and selective re-treatment leads to improved clinical outcome as well. Currently available animal-derived surfactants are superior to non-protein-containing synthetic surfactants. Ongoing evaluation will determine if important differences in animal-derived products are noted. Future trials will evaluate third-generation surfactant products and further refine what constitutes optimal use of surfactant.
INTRODUCTION
Of all the therapies during the neonatal period, none has probably been tested as extensively as surfactant replacement therapy. More than 400 clinical trials have evaluated the overall efficacy of surfactant therapy, as well as aspects such as the relative efficacy of different surfactant preparations, the optimal timing of administration and the optimal dosage. This brief overview focuses on specific practices in the use of surfactant replacement therapy and reviews the evidence supporting them.
What are the Proven Clinical Benefits of Surfactant?
Surfactant therapy leads to significant clinical improvement in infants at risk for, or having, respiratory distress syndrome (RDS). Multiple clinical trials from the late 1980 s and early 1990 s, which compared the effects of synthetic or animal-derived surfactant preparations to placebo or no therapy, provided clear estimates of the clinical effects of surfactant therapy. Surfactant therapy leads to rapid improvement in oxygenation and decreased ventilator support.
1-3 Systematic reviews of these trials [4] [5] [6] [7] show that, when compared to placebo or no therapy, surfactant treatment or prophylaxis (with either animal-derived or synthetic surfactant) results in a relative reduction of up to 40% in mortality risk and 30-65% in the risk of pneumothorax. However, no consistent effects on other clinical outcomes such as chronic lung disease, patent ductus arteriosus, and intraventricular hemorrhage are noted. Observational studies showing a decrease in mortality and morbidity of very low birth weight infants after the widespread introduction of surfactant therapy [8] [9] [10] [11] [12] [13] further substantiate the beneficial outcomes of surfactant therapy.
Long-term outcomes after surfactant therapy have not been studied as comprehensively as short-term morbidity and mortality. Outcomes are predominantly reported in the first 3 years of life, with sparse reports of outcomes at school age or higher. Although limited, evidence suggests that not only do more infants survive from surfactant therapy, these infants are at no selective disadvantage for neurodevelopmental sequelae due to the surfactant therapy. 10,14 -20 Which Surfactant Product is Most Effective? Two types of surfactant are currently available for clinical use: (1) surfactants derived from bovine or porcine lungs F 'natural' surfactants and (2) synthetic surfactants. The purification procedure for natural surfactants, including extraction with organic solvents removes the hydrophilic proteins SP-A and SP-D, leaving material containing only lipids and small amounts of hydrophobic proteins. 21 Current synthetic surfactants are comprised mostly of dipalmitoylphosphatidylcholine (DPPC) and do not contain any of the other phospholipids or apoproteins. A new generation of protein-or peptide-containing synthetic surfactants is under development and testing.
Although both synthetic and animal-derived surfactants are effective in clinical trials, animal-derived surfactants contain surfactant-specific proteins that may aid in surfactant adsorption and resist surfactant inactivation, and consequently have a more rapid onset of action than synthetic surfactant, allowing ventilator settings and inspired oxygen concentrations to be lowered faster.
A systematic review 26 of the 10 randomized trials that studied the effects of animal-derived versus synthetic surfactant for the treatment of RDS 23,24,27 -34 supports the use of animal-derived surfactants. Compared to synthetic surfactant, treatment with animal-derived surfactant extracts decreased the risks of pneumothorax (typical relative risk (RR) 0.63, 95% CI 0.52, 0.76) and mortality (typical RR 0.87, 95% CI 0.75, 0.99). There were no significant differences in risks of chronic lung disease, intraventricular hemorrhage, sepsis or patent ductus arteriosus.
Fewer randomized trials have compared the efficacy and adverse effects of different animal-derived surfactant products. Trials comparing beractant (Survanta s , Ross Laboratories, Columbus, OH (a lipid extract of bovine lung mince)] and calf lung surfactant extract (Infasurf s , Forest Labs, New York, NY (a lipid extract derived from bovine lung washes)) demonstrated no differences in clinical outcomes or dosing complications. 35 However, among infants treated for established RDS, a subgroup of those who received calf lung surfactant extract had a significantly longer interval between doses, a lower inspired oxygen concentration, and a lower mean airway pressure in the first 48 hours of life than infants treated with beractant. Among infants treated prophylactically, mortality in infants with birth weight <600 g was significantly higher with calf lung surfactant extract than with beractant.
Two studies compared poractant alfa (Curosurf s , DEY LP, Napa, CA, Chiesi Farmaceutica, Parma, IT), a lipid extract derived from minced porcine lung and beractant. 36, 37 In both studies, infants treated with poractant alfa had a more rapid initial improvement in oxygenation, reduced ventilator requirements compared to infants, and fewer additional doses (with the 200 mg/ kg group) as compared with those treated with beractant. The trials had insufficient power to detect true differences in important clinical outcomes (i.e., overall long-term mortality, complication rates) between the two groups, as these were designed to assess FI0 2 response as the primary end point. In Ramanathan's study, two dose levels of poractant alfa (200 and 100 mg/kg) were compared to beractant (100 mg/kg). In a subgroup of infants less than 32 weeks gestation, the group that received the 200 mg/kg dose of poractant alfa had a higher rate of survival than the other two (100 mg/kg dose) groups at 36 weeks corrected age. Although these observations are interesting, it is unclear whether this improvement reflects the difference in initial dosage difference or other product differences. Based on the initial data from these clinical trials, it would be difficult to declare one animal-derived surfactant product to be clearly superior to others.
Does Surfactant Dosing and Administration Technique Matter?
Administration technique. Based on the administration technique used in the original clinical trials, each surfactant product has administration recommendations that may or may not be supported by good evidence. In animal studies, pulmonary distribution of intratracheally instilled surfactant was largely determined by gravity, and was unaffected by changing the chest position after instillation. 38 Therefore, for neonates receiving surfactant, keeping the chest in the horizontal position may result in the most even distribution of the surfactant in the two lungs, with the least handling.
Although a slow infusion of surfactant would seem desirable, in animal studies, slow infusion of surfactant into the endotracheal tube results in nonhomogenous distribution of surfactant in the lung. 39, 40 Other methods of administration, such as nebulization or aerosolization 41 and in utero administration to the human fetus, 42 have also been reported. These methods are not currently recommended.
Re-treatment/multiple doses. Surfactant may become rapidly metabolized, and functional inactivation of surfactant can result from the action of soluble proteins and other factors in the small airways and alveoli. Multiple doses of surfactant are thought to be useful because they can overcome such inactivation. Two randomized controlled trials 43, 44 that compared multiple dosing regimens to single-dose regimens of animal-derived surfactant extract for treatment of established respiratory distress syndrome have been evaluated in a systematic review. 45 Approximately 70% of the infants randomized to the multiple dose regimens received multiple doses. The meta-analysis supports a decreased risk of pneumothorax associated with multiple-dose surfactant therapy (typical RR 0.51, 95% CI 0.30, 0.88). There was also a trend towards decreased mortality (typical RR 0.63, 95% CI 0.39, 1.02). No differences were detected in other clinical outcomes. However, it is unclear how many repeat doses should be administered. In the OSIRIS trial, which used synthetic surfactant, a two-dose treatment schedule was found to be equivalent to a treatment schedule permitting up to four doses of surfactant. 46 Two studies addressed the criteria for administration of repeat doses of animal-derived surfactant. 47, 48 In general, liberal retreatment criteria did not lead to significant clinical improvement in the overall groups studied, but in one study a subgroup of sicker infants benefited from a lower administration threshold. 48 
Is the Timing of Surfactant Administration Important?
The initial trials of surfactant proved that either prophylactic treatment or selective treatment of infants with RDS was successful. A prophylactic surfactant approach is supported by the more uniform and homogenous distribution of surfactant when it is administered into a fluid-filled animal lung, 49, 50 and by the belief that administration of surfactant into a previously unventilated or minimally ventilated lung diminishes acute lung injury. 51, 52 Eight randomized controlled trials, all of which used animal-derived surfactant preparations (either poractant alfa and beractant), compared the effects of prophylactic surfactant administration to surfactant treatment of established RDS. [53] [54] [55] [56] [57] [58] [59] [60] With prophylaxis, surfactant was administered before 15 min of age. With selective treatment, it was administered at mean times ranging from 1.5 to 7.4 hours. There are no trials comparing prophylactic surfactant administration to very early selective administration, for example at 30 to 60 minutes of life. In the overview of these trials, compared to surfactant treatment of established RDS, prophylactic surfactant decreased the risks of pneumothorax (typical RR 0.62, 95% CI 0.42, 0.89), pulmonary interstitial emphysema (typical RR 0.54, 95% CI 0.36, 0.82), and neonatal mortality (typical RR 0.61, 95% CI 0.48, 0.77), with a trend noted toward a decrease in the risk of intraventricular hemorrhage (typical RR 0.92, 95% CI 0.82, 1.03).
Institutions will need to individually evaluate at what point these benefits from prophylactic surfactant exceed the potential risks of endotracheal intubation, and the costs of surfactant dosing to infants who would not have required it. Although most studies used an upper gestation limit of 30 weeks to determine the eligibility for surfactant prophylaxis, others have proposed upper gestations of 29 61 or 28 weeks. 62 Surfactant prophylaxis administered after initial resuscitation has equivalent or greater efficacy than administration as a bolus after immediate postdelivery intubation 63 and therefore administration ''prior to the first breath'' is unnecessary.
Preterm infants who do not receive prophylaxis but have RDS should be treated as early as possible, based on the same physiologic mechanisms supporting surfactant prophylaxis and on four randomized controlled trials that evaluated early versus delayed selective surfactant administration. 46, [64] [65] [66] These are summarized in a systematic review. 67 Two of these studies used animal-derived surfactants and two used synthetic surfactant. Early administration of surfactant, defined in different studies as administration of the first dose of surfactant within the first 30 minutes, the first hour or the first 2 hours of life, resulted in a decrease in the risk of pneumothorax (typical RR 0.70, 95% CI 0.59, 0.82), a decrease in the risk of pulmonary interstitial emphysema (typical RR 0.63, 95% CI 0.43,0.93), a decrease in the risk of chronic lung disease (requirement for supplemental oxygen at 36 weeks gestation, typical RR 0.70, 95% CI 0.55, 0.88), and a decrease in the risk of neonatal mortality (typical RR 0.87, 95% CI 0.77, 0.99).
Therefore, in preterm infants who do not receive prophylactic surfactant, the first dose of surfactant should be administered as early as possible. Outborn infants are at highest risk of delayed administration. Tertiary hospitals accepting outborn neonates for intensive care should develop systems to ensure early surfactant administration to these infants. For example, to avoid delays, surfactant can be administered by the transporting team or by the referring hospital. In inborn infants, early administration should be ensured by prioritizing surfactant administration over other admission procedures that can cause delays, such as umbilical catheter placement, radiographs, and nursing procedures.
Conclusions
Surfactant replacement therapy represents a significant advance in the management of preterm infants with respiratory distress syndrome and has become established as a standard part of the management of such infants. Both animal-derived and synthetic surfactants lead to clinical improvement and decreased mortality, with animal-derived surfactants having additional advantages over synthetic surfactants. The use of prophylactic surfactant, administered after initial stabilization at birth, to infants at risk for respiratory distress syndrome has benefits over ''rescue'' surfactant given to treat infants with established respiratory distress syndrome. In infants who do not receive prophylaxis, earlier treatment (before two hours of life) has benefits over later treatment. While use of multiple doses of surfactant appears to be more effective than the strict use of a single dose, there are other data to suggest that a larger up front dose may be significant. However, the exact threshold for retreatment has yet to be firmly established. Adverse effects of surfactant therapy are infrequent and usually not serious, and long-term follow-up of infants treated with surfactant in the neonatal period is reassuring. Future trials will evaluate third-generation surfactant products, clarify product differences, and further refine what constitutes optimal use of surfactant in conjunction with other respiratory interventions.
